Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Durvalumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Imfinzi (durvalumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.
Durvalumab Monotherapy 10mg/kg - 14 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 >= 1% on tumor cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).
Durvalumab Monotherapy 1500 mg - 28 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab for reimbursement as a monotherapy treatment option for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).